Nurix Therapeutics Q2 2026 Earnings
As seen on the 24/7 Wall St. homepage on July 9, 2026.
Q2 2026
EPS
$-0.81
est $-0.72
-13.1%
Revenue
$9M
est $15M
-40.9%
Nurix missed earnings and revenue badly, but the $700 million Roche upfront arriving next quarter will vault cash to $1.14 billion and fund the leap into Phase 3 trials for lead BTK degrader bexobrutideg. The quarterly flop fades against a transformative collaboration that validates targeted protein degradation as the field's future.
Mentioned: NRIX